TECH Revenue per Share 7.21 - GuruFocus.com
| TE1 Stock | 55.50 0.50 0.91% |
Slightly above 53% of Bio Techne's investor base is interested to short. The analysis of current outlook of investing in Bio Techne Corp suggests that many traders are impartial regarding Bio Techne's prospects. Bio Techne's investing sentiment can be driven by a variety of factors including economic data, Bio Techne's earnings reports, geopolitical events, and overall market trends.
Bio |
TECH Revenue per Share 7.21 GuruFocus.com
Read at news.google.com
 |
Bio Techne Fundamental Analysis
We analyze Bio Techne's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Bio Techne is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Bio Techne Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bio Techne stock to make a market-neutral strategy. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics with similar companies.
Peers
Bio Techne Related Equities
| AM8 | AMAG Austria | 5.79 | ||||
| A4A | ANGLO ASIAN | 5.44 | ||||
| XYD | MINCO SILVER | 0.00 | ||||
| I43 | Jacquet Metal | 0.48 | ||||
| YZC | Yanzhou Coal | 0.97 | ||||
| G1MN | Globex Mining | 1.03 |
Additional Tools for Bio Stock Analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.